# Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma

Submission date Recruitment status Prospectively registered 19/08/2002 No longer recruiting [ ] Protocol [ ] Statistical analysis plan Registration date Overall study status 19/08/2002 Completed [X] Results Individual participant data **Last Edited** Condition category 30/10/2019 Cancer

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr - -

#### Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

**Secondary identifying numbers** NHS 1

# Study information

### Scientific Title

Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma

### **Study objectives**

Not provided at time of registration

# Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Carcinoma of the pancreas

#### **Interventions**

- 1. Group A: Flutamide 250 mg three times daily
- 2. Group B: Placebo

### Intervention Type

Drug

#### Phase

Phase III

# Drug/device/biological/vaccine name(s)

Drogenil (flutamide)

### Primary outcome measure

Not provided at time of registration

### Secondary outcome measures

Not provided at time of registration

### Overall study start date

01/01/1995

# Completion date

31/01/1997

# **Eligibility**

### Key inclusion criteria

Not provided at time of registration

### Participant type(s)

**Patient** 

### Age group

**Not Specified** 

### Sex

**Not Specified** 

### Target number of participants

Not provided at time of registration

### Key exclusion criteria

Not provided at time of registration

### Date of first enrolment

01/01/1995

### Date of final enrolment

31/01/1997

# Locations

# Countries of recruitment

England

**United Kingdom** 

# Study participating centre MRC Clinical Trials Unit

London United Kingdom NW1 2DA

# Sponsor information

# Organisation

Schering-Plough Ltd (UK)

### Sponsor details

Schering-Plough House Shire Park Welwyn Garden City United Kingdom AL7 1TW

### Sponsor type

Industry

### **ROR**

https://ror.org/00148fb49

# Funder(s)

# Funder type

Industry

#### **Funder Name**

Schering-Plough Ltd (UK)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	presumed results	27/06/1998	30/10/2019	Yes	No